Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.45 |
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD1 | P21728 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | MTR | Q99707 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230361 | 0.89 | DRD3 (0.44) | DRD3DRD2DRD1DRD4MTR | |
| SCHEMBL7229186 | 0.89 | DRD2 (0.46) | DRD3DRD2DRD1DRD4HTR1A | |
| SCHEMBL7228845 | 0.88 | DRD2 (0.47) | DRD3DRD2DRD1DRD4MTR | |
| SCHEMBL7229472 | 0.87 | DRD3 (0.50) | DRD3DRD2DRD1DRD4MTR | |
| SCHEMBL7228555 | 0.85 | DRD4 (0.48) | HTR7DRD3DRD2DRD1DRD4 | |
| SCHEMBL7228591 | 0.85 | DRD3 (0.42) | DRD3DRD2DRD1DRD4HTR1A | |
| SCHEMBL7230735 | 0.84 | DRD2 (0.53) | DRD3DRD2DRD1DRD4HTR1A | |
| SCHEMBL7238192 | 0.83 | ADRA1D (0.48) | DRD3DRD2DRD1DRD4HTR1A | |
| SCHEMBL7229724 | 0.83 | DRD2 (0.44) | DRD3DRD2DRD1DRD4HTR1A | |
| SCHEMBL7238667 | 0.83 | DRD2 (0.44) | DRD3DRD2DRD1DRD4MTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583144-B2 | Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | OHKURA NAOTO (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6417362-B1 | PIPERAZINE DERIVATIVES; ARTERIOSCLEROSIS, PANCREATITIS, AND CARDIOVASCULAR DISORDER TREATMENT; SIDE EFFECT REDUCTION | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-0999208-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | APOB, PNLIP, NR1H2 | HTR7 2786/4885DRD3 1470/4885DRD2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.